Clinical Trial Update: Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating NK cells derived from Sibship to treat recurrence of hepatocellular carcinoma after liver transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• NK cells from Sibship (natural killer cells)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: UNKNOWN